Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195814 · ClinicalTrials.gov registry record
A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
A clinical trial of Psoriatic Arthritis, sponsored by Pfizer.
- Completed
- Registry status
- 141
- Enrollment target
- 1
- Study location
NCT05195814: Completed study of Psoriatic Arthritis, sponsored by Pfizer.
NCT05195814 is a study of Psoriatic Arthritis that has completed, run by Pfizer. The registered enrollment target is 141 participants, below the 850-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05195814, a study of Psoriatic Arthritis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine for the potential treatment of Psoriatic Arthritis (PsA). Psoriatic Arthritis is a joint swelling disease that can also affect the skin, nails and eyes. The study medicine is called Tofacitinib. This study is seeking participants who: * Started taking tofacitinib alone or with other approved medicines (eg. methotrexate, leflunomide, sulfasalazine, apremilast) for PsA disease. We will only look at participants' who started tofacitinib after December 14, 2017. * Have a 6-month follow-up visit (with a 3-month window) This is an observational study. Participants receiving Tofacitinib will be included to assess how well tofacitinib works. We will look at participants' demographic information and therapy history. We will also monitor participants' disease progression before and 6 months after treatment. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.
Primary Outcome
Tender joint count (TJC) 68 is a method of assessing joint inflammation. Number of tender joints was determined by examining 68 joints and identifying the joints that were painful under pressure or to passive motion. The joints examined included the temporomandibular (n = 2), sternoclavicular (n = 2), acromioclavicular (n = 2), shoulder (n = 2), elbow (n = 2), wrist (n = 2), metacarpophalageal (n = 10), interphalangeal of thumb (n = 2), distal interphalangeal (n = 8), proximal interphalangeal (n
Conditions Studied
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2023-10-31 |
What the finished NCT05195814 record still lists
NCT05195814 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 850-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT05195814 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05195814 about?
NCT05195814 is a clinical study titled "A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis". The purpose of this study is to learn about the safety and effects of the study medicine for the potential treatment of Psoriatic Arthritis (PsA). Psoriatic Arthritis is a joint swelling disease that can also affect the skin, nails and eyes. The study medicine is called Tofacitinib. This study is se...
What is the current status of trial NCT05195814?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2021-11-15. Estimated completion is 2023-10-31.
What conditions does trial NCT05195814 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
Who is sponsoring clinical trial NCT05195814?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05195814 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05195814's enrollment target sits among peer trials
141 31st of 48 higher than 18 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Stronger Together Psoriatic Arthritis Wellness Study
RECRUITING
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI